The U.K. is launching a coordinated national program of research into the unprecedented outbreak of monkeypox that has spread across Europe and North America – regions where the disease is not endemic – over the past six months. Taking a lead from the SARS-CoV-2 playbook, there will be work to sequence the viral genome and to study how it is evolving, linking this to changes in the transmission and pathology of the virus.
A group of scientists from The Ohio State University (OSU) in collaboration with the University of Chicago has found that targeting the enzyme NSUN2 could be used against a wide range of viruses. Its deficiency could stop infection by inhibiting gene expression and viral replication.
Three years after WHO declared the COVID-19 pandemic, some patients are still reporting symptoms from long-ago infections. And the scientific community is studying the reasons for the post-acute sequelae of SARS-CoV-2 (PASC). Until now, the studies provided varied reasons related to persistent COVID or PASC, such as acute SARS-CoV-2 injury in different organs, or reservoirs of the virus in certain tissues, as it happens with other pathogens like HIV. At the IDWeek 2022 infectious disease conference held this week in Washington, D.C., Eric Daar, chief of the Division of HIV Medicine at the Lundquist Institute at Harbor-UCLA Medical Center, moderated the session, 'COVID-19: Post-acute sequelae', where talks offered new results on the symptoms of people who have suffered prolonged COVID during the pandemic.
The U.K. is launching a coordinated national program of research into the unprecedented outbreak of monkeypox that has spread across Europe and North America – regions where the disease is not endemic – over the past six months. Taking a lead from the SARS-CoV-2 playbook, there will be work to sequence the viral genome and to study how it is evolving, linking this to changes in the transmission and pathology of the virus.
Chemoproteomics studies have uncovered multiple potential kinase drug targets in the Plasmodium protozoan that causes malaria, and subsequent screening of approved kinase inhibitor drugs has now thrown up several hits with lethal activity at different stages of the complex life cycle of the parasite. Researchers at the University of Cape Town, South Africa, working with scientists at Glaxosmithkline plc, describe the activity in Plasmodium of one of these kinase inhibitors, the cancer drug sapanisertib, in a paper appearing in Science Translational Medicine, Oct. 19, 2022.
Anti-SARS-CoV-2 monoclonal antibody (MAb) pair COV2-2196 (tixagevimab, class I) and COV2-2130 (cilgavimab, class III) are human neutralizing Abs (nAbs) that target nonredundant, complementary epitopes within the receptor binding domain of SARS-CoV-2 spike protein (S-RBD).
Nanoviricides Inc. has completed its IND-enabling preclinical drug development tasks pertaining to NV-CoV-2 for the treatment of SARS-CoV-2 infection and is working to prepare an IND application to submit to the FDA.
RSS
